Insight

Reference

·

Primary source

CBD wellness THC threshold

<0.2% THC

As of2024 regulation·Sources1·Primary

Regulatory ceiling for hemp-derived CBD wellness, cosmetics, supplements; product above threshold falls back under prescription / narcotic control.

Download CSV ↓Compare plans →

Figure in context

Regulatory ceiling for hemp-derived CBD wellness, cosmetics, supplements; product above threshold falls back under prescription / narcotic control.

Regulatory ceiling for hemp-derived CBD wellness, cosmetics, supplements; product above threshold falls back under prescription / narcotic control.

Time scope

2024 regulation

Source basis

Primary source

Interpretation notes

What this tells you

Regulatory ceiling for hemp-derived CBD wellness, cosmetics, supplements; product above threshold falls back under prescription / narcotic control.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

FY2024
~THB 18B

Thailand medical cannabis, CBD market size

MoPH FDA, GPO, industry triangulation

2022-2023 peak
~THB 35B

Grey-boom peak market

Industry estimate, trade-body triangulation

2022 policy
2022

Cannabis decriminalisation year

MoPH, Royal Thai Gazette

FY2024
5 key names

SET-listed cannabis exposures

SET filings

Report context

Thailand Medical Cannabis & CBD Market Intelligence

Thailand's cannabis regulatory journey: 2022 decriminalisation made Thailand the first Asian country to remove cannabis from its Category 5 narcotic schedule; 2024-25 re-regulation returned the market to medical-only, CBD wellness, licensed retail, closing the earlier grey retail boom. Segments now legal: prescription medical cannabis (MoPH FDA, GPO Government Pharmaceutical Organization channels), CBD wellness, cosmetics, supplements (< 0.2% THC threshold), hemp-extract processing, export, pharma-grade cannabis extract (GPO manufacturing). Listed exposures: DOD Biotech (SET: DOD), STA (SET: STA — Sri Trang Agro-Industry cannabis subsidiary), Rojukiss (SET: KISS) CBD cosmetics, CP Axtra (SET: CPAXT) pharmacy cannabis pilots, GBS Group pharmacy-clinic network. Market reset 2024 from ~THB 35B grey-boom peak to ~THB 18B medical, wellness only. Regulatory risk remains the primary investor variable.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Bangkok Dusit Medical Services

Thailand's largest listed hospital group — 50+ hospitals across six brand families; >THB 110B FY2024 revenue.

Bumrungrad Hospital

Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.

CP Axtra (Makro, Lotus)

CP Group post-2022 Makro, Lotus amalgamation; Makro wholesale, Lotus hypermarkets; FY2024 revenue ~THB 480-500B; Chearavanont-controlled.

Government Pharmaceutical Organisation (GPO)

Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.

Sri Trang Agro-Industry

Listed world-leading natural rubber processor, parent of STGT gloves; vertical integration moat.

CBD wellness THC threshold · Insight